Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
TTHI's Cash to Debt is ranked higher than
93% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. TTHI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
TTHI' s Cash to Debt Range Over the Past 10 Years
Min: 4.13  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
TTHI's Interest Coverage is ranked higher than
90% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. TTHI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
TTHI' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: 9999.99
Current: No Debt
N/A
9999.99
F-Score: 3
Z-Score: -7.52
M-Score: -3.07
WACC vs ROIC
20.98%
-17690.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -69.61
TTHI's ROE (%) is ranked lower than
73% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. TTHI: -69.61 )
Ranked among companies with meaningful ROE (%) only.
TTHI' s ROE (%) Range Over the Past 10 Years
Min: -107.15  Med: -40.61 Max: 39.57
Current: -69.61
-107.15
39.57
ROA (%) -55.68
TTHI's ROA (%) is ranked lower than
74% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. TTHI: -55.68 )
Ranked among companies with meaningful ROA (%) only.
TTHI' s ROA (%) Range Over the Past 10 Years
Min: -86.61  Med: -30.98 Max: 27.8
Current: -55.68
-86.61
27.8
ROC (Joel Greenblatt) (%) -15258.52
TTHI's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. TTHI: -15258.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TTHI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -31219.37  Med: -2147.03 Max: 2522.74
Current: -15258.52
-31219.37
2522.74
EBITDA Growth (3Y)(%) 51.20
TTHI's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. TTHI: 51.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TTHI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -3.00 Max: 51.2
Current: 51.2
0
51.2
EPS Growth (3Y)(%) 42.80
TTHI's EPS Growth (3Y)(%) is ranked higher than
90% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. TTHI: 42.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TTHI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -20.7  Med: -6.90 Max: 51.8
Current: 42.8
-20.7
51.8
» TTHI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-09-14)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

TTHI Guru Trades in Q2 2015

Jim Simons 179,300 sh (-5.98%)
» More
Q3 2015

TTHI Guru Trades in Q3 2015

Jim Simons 204,200 sh (+13.89%)
» More
Q4 2015

TTHI Guru Trades in Q4 2015

Jim Simons 236,400 sh (+15.77%)
» More
Q1 2016

TTHI Guru Trades in Q1 2016

Jim Simons 261,000 sh (+10.41%)
» More
» Details

Insider Trades

Latest Guru Trades with TTHI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:LSE:IMM, ROCO:4186, XPAR:ALQGC, ASX:AHZ, OSTO:BINV, OTCPK:RGRX » details
Traded in other countries:TTH.Canada, RFYA.Germany,
Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company is engaged in developing therapeutics for disease indications with markets. Its technologies are focused on the treatment of Alzheimer's disease and diabetes.

Transition Therapeutics Inc was incorporated on July 6, 1998 as 'Transition Therapeutics and Diagnostics Inc.' The Corporation filed articles of amendment on October 12, 2000 and on October 19, 2000 to create a class of non-voting shares (the 'Class B Shares') and to amend certain attributes of its Common Shares. On November 2, 2000, the Corporation filed articles of amendment to delete its private company restrictions. On December 14, 2000, the Corporation filed articles of amendment to change its name to 'Transition Therapeutics Inc.' The Company's technologies are focused on the treatment of Alzheimer's disease and diabetes. The Corporation operates in one business segment; that is the research and development of therapeutic agents. Its technologies in development include ELND005 (AZD-103) for the treatment of Alzheimer's disease. On April 30, 2013, the Company announced the results of a five-week proof of concept clinical study of TT401 in type 2 diabetic and obese non-diabetic subjects. In the study, TT401, a once weekly administered peptide, demonstrated improvements in glycemic control and reductions in body weight.

Ratios

vs
industry
vs
history
P/B 1.50
TTHI's P/B is ranked higher than
83% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. TTHI: 1.50 )
Ranked among companies with meaningful P/B only.
TTHI' s P/B Range Over the Past 10 Years
Min: 0.58  Med: 2.76 Max: 7.54
Current: 1.5
0.58
7.54
Current Ratio 11.01
TTHI's Current Ratio is ranked higher than
79% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. TTHI: 11.01 )
Ranked among companies with meaningful Current Ratio only.
TTHI' s Current Ratio Range Over the Past 10 Years
Min: 2.24  Med: 9.79 Max: 30.83
Current: 11.01
2.24
30.83
Quick Ratio 11.01
TTHI's Quick Ratio is ranked higher than
79% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. TTHI: 11.01 )
Ranked among companies with meaningful Quick Ratio only.
TTHI' s Quick Ratio Range Over the Past 10 Years
Min: 1.66  Med: 9.79 Max: 30.83
Current: 11.01
1.66
30.83

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.16
TTHI's Price/Net Cash is ranked higher than
82% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. TTHI: 2.16 )
Ranked among companies with meaningful Price/Net Cash only.
TTHI' s Price/Net Cash Range Over the Past 10 Years
Min: 2.13  Med: 6.24 Max: 64
Current: 2.16
2.13
64
Price/Net Current Asset Value 2.11
TTHI's Price/Net Current Asset Value is ranked higher than
84% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. TTHI: 2.11 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TTHI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.54  Med: 5.75 Max: 40
Current: 2.11
1.54
40
Price/Tangible Book 2.11
TTHI's Price/Tangible Book is ranked higher than
75% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. TTHI: 2.11 )
Ranked among companies with meaningful Price/Tangible Book only.
TTHI' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.52  Med: 5.10 Max: 38.64
Current: 2.11
1.52
38.64
Earnings Yield (Greenblatt) (%) -166.65
TTHI's Earnings Yield (Greenblatt) (%) is ranked lower than
95% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. TTHI: -166.65 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TTHI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -191.08  Med: 87.60 Max: 486
Current: -166.65
-191.08
486

More Statistics

EPS (TTM) $ -0.50
Beta2.36
Short Percentage of Float1.27%
52-Week Range $0.70 - 9.30
Shares Outstanding (Mil)38.88

Analyst Estimate

Jun16 Jun17 Jun18 Jun19
Revenue (Mil $) 4 7
EPS ($) -0.28 -0.42 -0.42 -0.28
EPS without NRI ($) -0.28 -0.42 -0.42 -0.28
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for TTHI

Headlines

Articles On GuruFocus.com
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 

More From Other Websites
Transition Therapeutics posts 3Q loss May 11 2016
Transition Therapeutics posts 3Q loss May 11 2016
Transition Therapeutics Announces Third Quarter Fiscal 2016 Financial Results May 11 2016
Transition Therapeutics Announces Third Quarter Fiscal 2016 Financial Results May 11 2016
Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2016 Financial Results on... May 09 2016
Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2016 Financial Results on... May 09 2016
Transition Therapeutics Announces Dosing of First Patient in Phase 2 Study of Drug Candidate TT701 Apr 25 2016
Transition Therapeutics Announces Dosing of First Patient in Phase 2 Study of Drug Candidate TT701 Apr 25 2016
Transition Therapeutics Provides Update on Type 2 Diabetes Drug Candidate TT401 Apr 18 2016
Transition Therapeutics Provides Update on Type 2 Diabetes Drug Candidate TT401 Apr 18 2016
Transition Therapeutics Receives Notification From NASDAQ Mar 17 2016
Transition Therapeutics Receives Notification From NASDAQ Mar 17 2016
Transition Therapeutics to Present at the 36th Annual Cowen Healthcare Conference Mar 01 2016
Transition Therapeutics to Present at the 36th Annual Cowen Healthcare Conference Mar 01 2016
Transition Therapeutics posts 2Q loss Feb 09 2016
Transition Therapeutics posts 2Q loss Feb 09 2016
Transition Therapeutics Announces Second Quarter Fiscal 2016 Financial Results Feb 09 2016
Transition Therapeutics Announces Second Quarter Fiscal 2016 Financial Results Feb 09 2016
Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2016 Financial Results on... Feb 05 2016
Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2016 Financial Results on... Feb 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)